Attached files

file filename
8-K - 8-K - MAGELLAN HEALTH INCa13-22662_18k.htm

Exhibit 99.1

 

GRAPHIC

NEWS RELEASE



Media Contact: David Carter, dwcarter@magellanhealth.com, (860) 507-1909
Investor Contact: Renie Shapiro, rshapiro@magellanhealth.com, (877) 645-6464

 

MAGELLAN HEALTH SERVICES REPORTS

THIRD QUARTER 2013 FINANCIAL RESULTS

 

- Updates 2013 Guidance -

 

AVON, Conn. — October 24, 2013 — Magellan Health Services Inc. (NASDAQ: MGLN) today reported financial results for the third quarter 2013, as summarized below. For the quarter ended September 30, 2013, the company reported net revenue of $873.6 million, segment profit of $59.2 million, and net income of $47.2 million or $1.70 per diluted common share. Segment profit represents income from operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits and income taxes.

 

Financial Results

 

 

 

Three Months Ended September 30

 

Nine Months Ended September 30

 

(Millions, except per share results)

 

2013

 

2012

 

Increase/
(Decrease)

 

2013

 

2012

 

Increase/
(Decrease)

 

Revenue

 

$

873.6

 

$

798.4

 

9.4

%

$

2,538.1

 

$

2,377.1

 

6.8

%

Segment Profit

 

59.2

 

69.4

 

(14.7

)%

203.5

 

189.6

 

7.3

%

Net Income

 

47.2

 

66.3

 

(28.8

)%

106.8

 

114.0

 

(6.3

)%

Earnings Per Share

 

1.70

 

2.36

 

(28.0

)%

3.87

 

4.10

 

(5.6

)%

 

As of September 30, 2013, the company had unrestricted cash and investments of $355.9 million, prior to the closing of the Partners Rx transaction on October 1.

 

“Magellan had a solid quarter, and we made significant progress in advancing our growth strategies,” said Barry M. Smith, chief executive officer.

 

“This is a particularly dynamic time as we continue to transform the company and position it for the changing health care market and for future growth.  In Magellan Complete Care, we received notice of a contract award from the state of Florida to launch a Medicaid specialty plan for individuals with Serious Mental Illness (SMI), and we signed definitive agreements for a strategic investment in AlphaCare of New York, a newly-licensed Medicaid Managed Long Term Care HMO and Medicare Plan.  We also completed the acquisition of Partners Rx, a full-service commercial pharmacy benefits management company with a strong focus on health plans and self-funded employers.

 

“We’ve added two highly experienced business leaders to our executive team.  Bob Field, President and CEO of Partners Rx, has become the CEO of Magellan Pharmacy Solutions, which includes all of our pharmacy products.  Additionally, Sam Srivastava, has been appointed to the new position of CEO of Magellan Plan Services, which includes our core

 



 

commercial and public sector behavioral health businesses, as well as Magellan Complete Care.  Bob and Sam are dynamic leaders with significant track records of success and innovation, and they, along with our entire executive team, are committed to taking the steps necessary to best position the company for continued future growth.”

 

Outlook

 

“Given the results to date, the expected fourth quarter impact of the Partners Rx acquisition, and the extension of our Maricopa County, AZ contract through March 31, 2014, we are now expecting our full year 2013 guidance for net revenue in the range of $3.5 to $3.7 billion, net income of $118 to $136 million, and segment profit in the upper half of our range of $245 to $265 million,” said Jonathan N. Rubin, chief financial officer.  “Taking into account the impact of share repurchase activity through October 21st, 2013, but not considering any potential future share repurchases, our guidance range for fully diluted EPS is estimated to be $4.28 to $4.93.

 

“Looking ahead, after adjusting the current 2013 segment profit guidance range for $15 million of net favorable, out-of-period adjustments, we currently expect that we will have moderately lower segment profit in 2014.  We will provide detailed 2014 guidance during our December call.”

 

Earnings Results Conference Call

 

Management will host a conference call at 10:00 a.m. Eastern Time on Thursday, October 24, 2013. To participate in the conference call, interested parties should call 1-800-857-1812 and reference the pass code Third Quarter Earnings Call 2013 approximately 15 minutes before the start of the call. The conference call will also be available via a live Webcast at Magellan’s investor relations page at www.MagellanHealth.com.

 

About Magellan Health Services: Headquartered in Avon, Conn., Magellan Health Services Inc. is a leading specialty health care management organization with expertise in managing behavioral health, radiology, and pharmacy benefits programs, as well as integrated health care programs for special populations. Magellan delivers innovative solutions to improve quality outcomes and optimize the cost of care for those we serve. As of September 30, 2013, Magellan’s customers include health plans, employers and government agencies, serving approximately 33.9 million members in our behavioral health business, 17.5 million members in our radiology benefits management segment, and approximately 9.2 million members in our medical pharmacy management product. In addition, the pharmacy solutions segment served 39 health plans and employers, 25 states and the District of Columbia, and several pharmaceutical manufacturers. For more information, visit www.MagellanHealth.com.

 

Cautionary Statement

 

This release contains forward-looking statements within the meaning of the Securities Exchange Act of 1934 and the Securities Act of 1933, as amended, which involve a number of risks and uncertainties. All statements, other than statements of historical information provided herein, may be deemed to be forward-looking statements including, without limitation, statements regarding estimates of 2013 revenue, net income, segment profit, out-of-period adjustments, and earnings per share, 2014 segment profit, and strategy and growth. These statements are based on management’s analysis, judgment, belief and expectation only as of the date hereof, and are subject to uncertainty and changes in

 



 

circumstances. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “may,” “should,” “could,” “estimate,” “intend” and other similar expressions are intended to identify forward-looking statements. Actual results could differ materially due to, among other things, the possible election of certain of the company’s customers to manage the health care services of their members directly; changes in rates paid to and/or by the company by customers and/or providers; higher utilization of health care services by the company’s risk members; delays, higher costs or inability to implement new business or other company initiatives; the impact of changes in the contracting model for Medicaid contracts; termination or non-renewal of customer contracts; the impact of new or amended laws or regulations; governmental inquiries; litigation; competition; operational issues; health care reform; and general business conditions. Additional factors that could cause actual results to differ materially from those reflected in the forward-looking statements include, but are not limited to, the risks discussed in the “Risk Factors” section included within the company’s Annual Report on Form 10-K for the year ended December 31, 2012, filed with the Securities and Exchange Commission on February 28, 2013, and the company’s subsequent Quarterly Reports on Form 10-Q filed during 2013. Readers are cautioned not to place undue reliance on these forward-looking statements. The company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date of this release. Segment profit information referred to herein may be considered a non-GAAP financial measure. Further information regarding this measure, including the reasons management considers this information useful to investors, are included in the company’s most recent Annual Report on Form 10-K and on subsequent Form 10-Qs.

 

Media Contact

David W. Carter

860-507-1909

DWCarter@MagellanHealth.com

 

Investor Contact

Renie Shapiro

877-645-6464

RShapiro@MagellanHealth.com

 

# # #

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended September 30,

 

Nine months Ended September 30,

 

 

 

2012

 

2013 (1)

 

2012

 

2013 (1)

 

 

 

 

 

 

 

 

 

 

 

Net revenue:

 

 

 

 

 

 

 

 

 

Managed care and other

 

$

711,092

 

$

775,957

 

$

2,114,149

 

$

2,255,748

 

Dispensing

 

87,345

 

97,641

 

262,974

 

282,359

 

Total net revenue

 

798,437

 

873,598

 

2,377,123

 

2,538,107

 

 

 

 

 

 

 

 

 

 

 

Cost and expenses:

 

 

 

 

 

 

 

 

 

Cost of care

 

516,238

 

570,187

 

1,543,361

 

1,642,944

 

Cost of goods sold

 

81,662

 

91,853

 

245,555

 

265,440

 

Direct service costs and other operating expenses (2)

 

135,574

 

156,834

 

412,496

 

440,958

 

Depreciation and amortization

 

15,239

 

17,654

 

45,172

 

50,770

 

Interest expense

 

537

 

789

 

1,713

 

2,191

 

Interest income

 

(350

)

(291

)

(1,619

)

(1,002

)

 

 

748,900

 

837,026

 

2,246,678

 

2,401,301

 

Income before income taxes

 

49,537

 

36,572

 

130,445

 

136,806

 

(Benefit) provision for income taxes

 

(16,725

)

(10,660

)

16,420

 

30,036

 

Net income

 

66,262

 

47,232

 

114,025

 

106,770

 

Other comprehensive income (loss) (3) 

 

120

 

110

 

208

 

(37

)

Comprehensive income

 

$

66,382

 

$

47,342

 

$

114,233

 

$

106,733

 

 

 

 

 

 

 

 

 

 

 

Weighted average number of common shares outstanding — basic

 

27,521

 

26,990

 

27,346

 

26,976

 

Weighted average number of common shares outstanding — diluted

 

28,042

 

27,704

 

27,835

 

27,563

 

 

 

 

 

 

 

 

 

 

 

Net income per common share — basic

 

$

2.41

 

$

1.75

 

$

4.17

 

$

3.96

 

Net income per common share — diluted

 

$

2.36

 

$

1.70

 

$

4.10

 

$

3.87

 

 


(1)   For a more detailed discussion of Magellan’s results for the quarterly period ended September 30, 2013, refer to the Company’s Quarterly Report on Form 10-Q, which will be filed with the SEC on Thursday, October 24, 2013, and the live broadcast or taped replay of the Company’s earnings conference call on Thursday, October 24, 2013, which will be available at www.MagellanHealth.com.

 

(2)   Includes stock compensation expense of $4,468 and $4,524 for the three months ended September 30, 2012 and 2013, respectively, and $13,935 and $14,764 for the nine months ended September 30, 2012 and 2013, respectively.

 

(3)   Net of income tax provision (benefit) of $78 and $74 for the three months ended September 30, 2012 and 2013, respectively, and $134 and $(25) for the nine months ended September 30, 2012 and 2013, respectively.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

 

 

 

Nine Months Ended September 30,

 

 

 

2012

 

2013 (1)

 

 

 

 

 

 

 

Cash flows from operating activities:

 

 

 

 

 

Net income

 

$

114,025

 

$

106,770

 

 

 

 

 

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

Depreciation and amortization

 

45,172

 

50,770

 

Non-cash interest expense

 

544

 

552

 

Non-cash stock compensation expense

 

13,935

 

14,764

 

Non-cash income tax expense (benefit)

 

12,395

 

(164

)

Non-cash amortization on investments

 

5,373

 

7,273

 

Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:

 

 

 

 

 

Restricted cash (2) 

 

(59,777

)

17,987

 

Accounts receivable, net

 

604

 

(19,231

)

Pharmaceutical inventory

 

(2,002

)

(1,680

)

Other assets

 

(4,218

)

(9,781

)

Accounts payable and accrued liabilities

 

(17,854

)

6,685

 

Medical claims payable and other medical liabilities

 

37,422

 

16,144

 

Tax contingencies

 

(34,616

)

(22,981

)

Other

 

654

 

4,174

 

Net cash provided by operating activities

 

111,657

 

171,282

 

 

 

 

 

 

 

Cash flows from investing activities:

 

 

 

 

 

Capital expenditures

 

(53,049

)

(42,091

)

Purchase of investments

 

(197,525

)

(235,946

)

Maturity of investments

 

215,150

 

233,723

 

Other

 

 

(7,900

)

Net cash used in investing activities

 

(35,424

)

(52,214

)

 

 

 

 

 

 

Cash flows from financing activities:

 

 

 

 

 

Payments to acquire treasury stock

 

 

(49,462

)

Proceeds from exercise of stock options and warrants

 

13,092

 

24,548

 

Payments on capital lease obligations

 

 

(2,310

)

Other

 

135

 

484

 

Net cash provided by (used in) financing activities

 

13,227

 

(26,740

)

 

 

 

 

 

 

Net increase in cash and cash equivalents

 

89,460

 

92,328

 

Cash and cash equivalents at beginning of period

 

119,862

 

189,464

 

Cash and cash equivalents at end of period

 

$

209,322

 

$

281,792

 

 


(1)           The Company’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2013 will be filed with the SEC on Thursday, October 24, 2013.

 

(2)           Includes the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change.  During the nine months ended September 30, 2012, restricted investments of $27,421 were shifted to restricted cash that resulted in an operating cash flow use, with restricted cash of $33,610 shifted to restricted investments during the nine months ended September 30, 2013 that resulted in an operating cash flow source.

 



 

MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

CONSOLIDATED OPERATING RESULTS BY BUSINESS SEGMENT

(Unaudited)

(In thousands)

 

 

 

Three Months Ended September 30,

 

Nine Months Ended September 30,

 

 

 

2012

 

2013 (1)

 

2012

 

2013 (1)

 

 

 

 

 

 

 

 

 

 

 

Managed care and other revenue

 

 

 

 

 

 

 

 

 

- Commercial

 

$

176,713

 

$

190,655

 

$

535,464

 

$

578,030

 

- Public Sector

 

407,265

 

445,260

 

1,206,289

 

1,266,739

 

- Radiology Benefits Management

 

88,126

 

94,125

 

253,809

 

277,118

 

- Pharmacy Solutions (2)

 

54,421

 

63,008

 

171,846

 

182,418

 

- Elimination (2) 

 

(15,433

)

(17,091

)

(53,259

)

(48,557

)

Total managed care and other revenue

 

711,092

 

775,957

 

2,114,149

 

2,255,748

 

 

 

 

 

 

 

 

 

 

 

Dispensing revenue - Pharmacy Solutions

 

87,345

 

97,641

 

262,974

 

282,359

 

 

 

 

 

 

 

 

 

 

 

Cost of care

 

 

 

 

 

 

 

 

 

- Commercial

 

100,973

 

118,022

 

323,992

 

354,520

 

- Public Sector (2) 

 

358,959

 

382,913

 

1,058,384

 

1,095,694

 

- Radiology Benefits Management

 

58,080

 

65,403

 

166,364

 

182,212

 

- Pharmacy Solutions

 

13,659

 

20,940

 

47,880

 

59,075

 

- Elimination (2) 

 

(15,433

)

(17,091

)

(53,259

)

(48,557

)

Total cost of care

 

516,238

 

570,187

 

1,543,361

 

1,642,944

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold - Pharmacy Solutions

 

81,662

 

91,853

 

245,555

 

265,440

 

 

 

 

 

 

 

 

 

 

 

Direct service costs and other operating expenses

 

 

 

 

 

 

 

 

 

- Commercial

 

43,007

 

47,032

 

127,825

 

129,823

 

- Public Sector

 

22,948

 

27,826

 

66,850

 

82,403

 

- Radiology Benefits Management

 

14,045

 

13,990

 

41,113

 

41,224

 

- Pharmacy Solutions

 

27,565

 

32,281

 

83,532

 

93,216

 

- Corporate

 

28,009

 

35,705

 

93,176

 

94,292

 

Total direct service costs and other operating expenses

 

135,574

 

156,834

 

412,496

 

440,958

 

 

 

 

 

 

 

 

 

 

 

Stock compensation expense (3)

 

 

 

 

 

 

 

 

 

- Commercial

 

(293

)

(124

)

(830

)

(390

)

- Public Sector

 

(278

)

(259

)

(835

)

(833

)

- Radiology Benefits Management

 

(419

)

(384

)

(1,179

)

(1,275

)

- Pharmacy Solutions

 

(238

)

(198

)

(704

)

(898

)

- Corporate

 

(3,240

)

(3,559

)

(10,387

)

(11,368

)

Total stock compensation expense

 

(4,468

)

(4,524

)

(13,935

)

(14,764

)

 

 

 

 

 

 

 

 

 

 

Segment profit (loss)

 

 

 

 

 

 

 

 

 

- Commercial

 

33,026

 

25,725

 

84,477

 

94,077

 

- Public Sector

 

25,636

 

34,780

 

81,890

 

89,475

 

- Radiology Benefits Management

 

16,420

 

15,116

 

47,511

 

54,957

 

- Pharmacy Solutions

 

19,118

 

15,773

 

58,557

 

47,944

 

- Corporate and Elimination

 

(24,769

)

(32,146

)

(82,789

)

(82,924

)

Total segment profit

 

$

69,431

 

$

59,248

 

$

189,646

 

$

203,529

 

 

 

 

 

 

 

 

 

 

 

Reconciliation of segment profit to income before income taxes:

 

 

 

 

 

 

 

 

 

Segment profit

 

$

69,431

 

$

59,248

 

$

189,646

 

$

203,529

 

Stock compensation expense

 

(4,468

)

(4,524

)

(13,935

)

(14,764

)

Depreciation and amortization

 

(15,239

)

(17,654

)

(45,172

)

(50,770

)

Interest expense

 

(537

)

(789

)

(1,713

)

(2,191

)

Interest income

 

350

 

291

 

1,619

 

1,002

 

Income before income taxes

 

$

49,537

 

$

36,572

 

$

130,445

 

$

136,806

 

 


(1)           The Company’s Quarterly Report on Form 10-Q for the nine months ended September 30, 2013 will be filed with the SEC on Thursday, October 24, 2013.

 

(2)           Public Sector has subcontracted with Pharmacy Solutions to provide pharmacy benefits management services on a limited risk basis for one of Public Sector’s customers.  As such, revenue and cost of care related to this intersegment arrangement are eliminated.

 

(3)           Stock compensation expense is included in direct service costs and other operating expenses; however, this amount is excluded from the computation of segment profit since it is managed on a consolidated basis.